Literature DB >> 12697809

Autoinhibition of the kit receptor tyrosine kinase by the cytosolic juxtamembrane region.

Perry M Chan1, Subburaj Ilangumaran, Jose La Rose, Avijit Chakrabartty, Robert Rottapel.   

Abstract

Genetic studies have implicated the cytosolic juxtamembrane region of the Kit receptor tyrosine kinase as an autoinhibitory regulatory domain. Mutations in the juxtamembrane domain are associated with cancers, such as gastrointestinal stromal tumors and mastocytosis, and result in constitutive activation of Kit. Here we elucidate the biochemical mechanism of this regulation. A synthetic peptide encompassing the juxtamembrane region demonstrates cooperative thermal denaturation, suggesting that it folds as an autonomous domain. The juxtamembrane peptide directly interacted with the N-terminal ATP-binding lobe of the kinase domain. A mutation in the juxtamembrane region corresponding to an oncogenic form of Kit or a tyrosine-phosphorylated form of the juxtamembrane peptide disrupted the stability of this domain and its interaction with the N-terminal kinase lobe. Kinetic analysis of the Kit kinase harboring oncogenic mutations in the juxtamembrane region displayed faster activation times than the wild-type kinase. Addition of exogenous wild-type juxtamembrane peptide to active forms of Kit inhibited its kinase activity in trans, whereas the mutant peptide and a phosphorylated form of the wild-type peptide were less effective inhibitors. Lastly, expression of the Kit juxtamembrane peptide in cells which harbor an oncogenic form of Kit inhibited cell growth in a Kit-specific manner. Together, these results show the Kit kinase is autoinhibited through an intramolecular interaction with the juxtamembrane domain, and tyrosine phosphorylation and oncogenic mutations relieved the regulatory function of the juxtamembrane domain.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12697809      PMCID: PMC153186          DOI: 10.1128/MCB.23.9.3067-3078.2003

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  41 in total

1.  Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.

Authors:  H Joensuu; P J Roberts; M Sarlomo-Rikala; L C Andersson; P Tervahartiala; D Tuveson; S Silberman; R Capdeville; S Dimitrijevic; B Druker; G D Demetri
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

Review 2.  Cell signaling by receptor tyrosine kinases.

Authors:  J Schlessinger
Journal:  Cell       Date:  2000-10-13       Impact factor: 41.582

3.  Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.

Authors:  M Mizuki; R Fenski; H Halfter; I Matsumura; R Schmidt; C Müller; W Grüning; K Kratz-Albers; S Serve; C Steur; T Büchner; J Kienast; Y Kanakura; W E Berdel; H Serve
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

4.  Interkinase domain of kit contains the binding site for phosphatidylinositol 3' kinase.

Authors:  S Lev; D Givol; Y Yarden
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-15       Impact factor: 11.205

5.  Assay of protein kinases using peptides with basic residues for phosphocellulose binding.

Authors:  J E Casnellie
Journal:  Methods Enzymol       Date:  1991       Impact factor: 1.600

6.  Investigating the substrate specificity of the HER2/Neu tyrosine kinase using peptide libraries.

Authors:  P M Chan; H P Nestler; W T Miller
Journal:  Cancer Lett       Date:  2000-11-28       Impact factor: 8.679

Review 7.  Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis.

Authors:  M Miettinen; J Lasota
Journal:  Virchows Arch       Date:  2001-01       Impact factor: 4.064

8.  Phosphorylation of tyrosine residues in the kinase domain and juxtamembrane region regulates the biological and catalytic activities of Eph receptors.

Authors:  K L Binns; P P Taylor; F Sicheri; T Pawson; S J Holland
Journal:  Mol Cell Biol       Date:  2000-07       Impact factor: 4.272

9.  A repressor sequence in the juxtamembrane domain of Flt-1 (VEGFR-1) constitutively inhibits vascular endothelial growth factor-dependent phosphatidylinositol 3'-kinase activation and endothelial cell migration.

Authors:  H Gille; J Kowalski; L Yu; H Chen; M T Pisabarro; T Davis-Smyth; N Ferrara
Journal:  EMBO J       Date:  2000-08-01       Impact factor: 11.598

10.  Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product.

Authors:  T Furitsu; T Tsujimura; T Tono; H Ikeda; H Kitayama; U Koshimizu; H Sugahara; J H Butterfield; L K Ashman; Y Kanayama
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

View more
  45 in total

Review 1.  Molecular basis and management of gastrointestinal stromal tumors.

Authors:  Ulas D Bayraktar; Soley Bayraktar; Caio M Rocha-Lima
Journal:  World J Gastroenterol       Date:  2010-06-14       Impact factor: 5.742

Review 2.  Defective downregulation of receptor tyrosine kinases in cancer.

Authors:  Kristi G Bache; Thomas Slagsvold; Harald Stenmark
Journal:  EMBO J       Date:  2004-07-01       Impact factor: 11.598

3.  The Rho GTP exchange factor Lfc promotes spindle assembly in early mitosis.

Authors:  Christopher J Bakal; Dina Finan; José LaRose; Clark D Wells; Gerald Gish; Sarang Kulkarni; Paulo DeSepulveda; Andrew Wilde; Robert Rottapel
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-23       Impact factor: 11.205

4.  Activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIP1L1-independent.

Authors:  Elizabeth H Stover; Jing Chen; Cedric Folens; Benjamin H Lee; Nicole Mentens; Peter Marynen; Ifor R Williams; D Gary Gilliland; Jan Cools
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-11       Impact factor: 11.205

5.  A CSF-1 receptor phosphotyrosine 559 signaling pathway regulates receptor ubiquitination and tyrosine phosphorylation.

Authors:  Ying Xiong; Da Song; Yunfei Cai; Wenfeng Yu; Yee-Guide Yeung; E Richard Stanley
Journal:  J Biol Chem       Date:  2010-11-01       Impact factor: 5.157

6.  The juxtamembrane region of the EGF receptor functions as an activation domain.

Authors:  Monica Red Brewer; Sung Hee Choi; Diego Alvarado; Katarina Moravcevic; Ambra Pozzi; Mark A Lemmon; Graham Carpenter
Journal:  Mol Cell       Date:  2009-06-26       Impact factor: 17.970

Review 7.  An update on molecular genetics of gastrointestinal stromal tumours.

Authors:  L Tornillo; L M Terracciano
Journal:  J Clin Pathol       Date:  2006-06       Impact factor: 3.411

Review 8.  Extracellular assembly and activation principles of oncogenic class III receptor tyrosine kinases.

Authors:  Kenneth Verstraete; Savvas N Savvides
Journal:  Nat Rev Cancer       Date:  2012-10-18       Impact factor: 60.716

Review 9.  A survival Kit for pancreatic beta cells: stem cell factor and c-Kit receptor tyrosine kinase.

Authors:  Zhi-Chao Feng; Matthew Riopel; Alex Popell; Rennian Wang
Journal:  Diabetologia       Date:  2015-02-03       Impact factor: 10.122

10.  The structural insights of stem cell factor receptor (c-Kit) interaction with tyrosine phosphatase-2 (Shp-2): an in silico analysis.

Authors:  Soumya Pati; Gangenahalli U Gurudutta; Om P Kalra; Asok Mukhopadhyay
Journal:  BMC Res Notes       Date:  2010-01-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.